New chemo plus ramucirumab for lung cancer after maintenance
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial studies a combination of chemotherapy (carboplatin and a “taxane”) plus ramucirumab for people with advanced lung cancer that came back or progressed after prior maintenance treatment. It may help by attacking cancer growth after earlier therapy no longer worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18+) with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC).
- You previously received 4 to 6 cycles of pemetrexed/carboplatin/pembrolizumab, and your cancer progressed after at least 18 weeks of maintenance pemetrexed and/or pembrolizumab.
- Your current daily functioning is good (PS 0 to 1), meaning you’re able to do most usual activities.
- You do NOT have a cancer “driver mutation” that can be treated with targeted medicines.
- You have no treatment-requiring other active cancer, no untreated brain metastases, and you do not have moderate-to-severe nerve numbness/tingling (sensory neuropathy grade 2 or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests new drug combinations for people with advanced or metastatic non-small cell lung cancer (NSCLC). Depending on your PD-L1 level and genetic profile, you may be placed in one of three groups to see if these combinations help shrink or control your tumor.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
This trial studies whether combining platinum chemotherapy with immune “checkpoint” medicine works better for people with stage IV lung cancer that has EGFR, ALK, or ROS1 mutations. It focuses on tumors that have grown again after first-line treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.